|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/5/2007 11:26:24 AM
ALACHUA, FL--(Marketwire - December 05, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases and cancer, announced today that Qualia Clinical Services, located in Omaha, Nebraska, has been selected to provide clinical site services for the Company's recently approved Phase 1b safety trial. The trial will be conducted in compliance with the approved FDA protocol and is designed to evaluate the safety and tolerability of the Company's SMaRT Replacement Therapy™ in healthy, adult male subjects over a six-week period, with a long-term follow-up evaluation at six months.
|
|
|
|
|
|
|
|
|
|
|